

## Disclosures

### Personal Commercial (24)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Amgen	Research/Research Grants ‡ <i>Da Vinci, FHSC</i>	Significant (>= \$5,000)	
Astra Zeneca	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Boehringer Ingelheim	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Cleerley	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Daiichi Sankyo	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Daiichi Sankyo	Research/Research Grants ‡ <i>EAS FHSC</i>	Significant (>= \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Esperion	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Menarini	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
MSD	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
New Amsterdam Pharma	Stock	Significant (>= \$5,000)	Prevention
New Amsterdam Pharma	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Nodthera	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis Corporation	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Novo Nordisk	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
PEMI31	Stock	Modest (< \$5,000)	Prevention
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	
Regeneron	Research/Research Grants ‡ <i>TOGETHER observational study</i>	Significant (>= \$5,000)	
Sanofi	Research/Research Grants ‡ <i>Investigator Initiated RCT of decision support tool to optimise clinical care</i>	Significant (>= \$5,000)	Prevention
SCRIBE	Stock	Significant (>= \$5,000)	Prevention
SCRIBE	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Silence Therapeutics	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Ultragenix	Research/Research Grants ‡ <i>PASS Registry</i>	Significant (>= \$5,000)	Prevention

### Additional Personal Commercial Disclosures for Education Activities (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Algorithm	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Amgen Inc.	Speaker's Bureau	Modest (< \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Daiichi Sankyo	Speaker's Bureau	Significant (>= \$5,000)	Prevention
Novartis Corporation	Speaker's Bureau	Significant (>= \$5,000)	Prevention

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Organon	Speaker's Bureau	Modest (< \$5,000)	Prevention
Torrent Pharmaceuticals	Speaker's Bureau	Modest (< \$5,000)	Prevention

### Personal Organizational or Other Non-Commercial (4)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Boehringer Ingelheim	Speaker's Bureau	Modest (< \$5,000)	Prevention
Novo Nordisk	Speaker's Bureau	Modest (< \$5,000)	Prevention
SANOFI	Speaker's Bureau	Modest (< \$5,000)	Prevention
Viartis	Speaker's Bureau	Modest (< \$5,000)	Prevention

### Clinical Trial Enroller (0)

No disclosures on record
--------------------------

### Institutional Financial Decision-Making Role (0)

No disclosures on record
--------------------------

### Expert Witness Testimony (0)

No disclosures on record
--------------------------

† Commercial Funding Source | ‡ Trial Name

### Agreement

**Certified Education Attestation** | Signed on 10/1/2025  
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/1/2025  
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 10/1/2025  
 URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 10/1/2025

### ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.